DNAJB5 Antibody

What is DNAJB5 and what are its primary functions in cellular biology?

DNAJB5 (DnaJ homolog subfamily B member 5) belongs to the heat shock protein 40 (HSP40) family of molecular chaperones. It functions primarily as a co-chaperone that supports HSP70 (HSPA)-dependent protein degradation via the proteasome pathway . DNAJB5 plays a crucial role in maintaining protein homeostasis (proteostasis) by preventing protein aggregation - a process implicated in various neurodegenerative disorders. The protein has been demonstrated to suppress destabilized protein aggregation through binding exposed hydrophobic patches in aggregation-prone clients . DNAJB5 is particularly notable for its protective effects against cytoplasmic TDP-43 protein aggregation in neurodegenerative disease models .

How can researchers distinguish DNAJB5 from other DNAJB family members in experimental systems?

Distinguishing DNAJB5 from other DNAJB family members requires attention to several key characteristics:

• Molecular weight: DNAJB5 has a predicted molecular weight of approximately 39 kDa

• Structural features: Unlike DNAJB6 and DNAJB8, DNAJB5 lacks the serine-rich stretch that is essential for preventing fibrillar aggregation

• Substrate binding: DNAJB5 has unique substrate binding properties that can be experimentally validated through co-immunoprecipitation studies

• Tissue distribution: DNAJB5 shows distinct expression patterns, with particular importance in cortical neurons

• Antibody specificity: Using antibodies raised against unique epitopes in DNAJB5, particularly those corresponding to regions that differ from other DNAJB proteins

When conducting Western blots, researchers should carefully validate antibody specificity using appropriate positive and negative controls, including recombinant proteins and knockout cell lines.

What are the optimal storage and handling conditions for DNAJB5 antibodies to maintain their efficacy?

For optimal performance of DNAJB5 antibodies, researchers should adhere to the following storage and handling protocols:

• Store unopened antibody at -20°C (do not aliquot in this state)

• After opening, prepare working aliquots to avoid repeated freeze-thaw cycles

• Store antibody in buffer containing 50% glycerol and 0.02% sodium azide at pH 7.3

• Avoid exposure to light and heat during storage and handling

• When using for applications, maintain cold chain protocols appropriate for protein-based reagents

• Check for visible precipitates before use and centrifuge if necessary

• Document lot numbers and validation data for reproducibility

Proper storage significantly affects experimental outcomes, particularly in sensitive applications like immunohistochemistry where epitope recognition can be compromised by suboptimal antibody handling.

What are the validated applications for DNAJB5 antibodies and their recommended dilutions?

Based on validated research protocols, DNAJB5 antibodies have been successfully employed in multiple experimental applications:

When optimizing experimental conditions, it is advisable to perform a dilution series to determine the optimal antibody concentration for each specific application and sample type. Validation has been conducted in multiple cell lines including Jurkat, HepG2, and HeLa cells .

How can researchers optimize Western blot protocols specifically for DNAJB5 detection?

To achieve optimal detection of DNAJB5 protein via Western blot, researchers should consider the following protocol optimizations:

• Sample preparation: Use whole cell lysates with complete protease inhibitor cocktails to prevent degradation

• Protein loading: Load approximately 30 μg of protein per lane for standard cell lines (e.g., Jurkat cells)

• Gel percentage: Utilize 10% SDS-PAGE for optimal separation near the 39 kDa range

• Transfer conditions: Use wet transfer with methanol-containing buffer for efficient protein transfer

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: Dilute DNAJB5 antibody to 1:500-1:1000 and incubate overnight at 4°C

• Washing: Perform stringent washing (4-5 times with TBST) to minimize background

• Detection system: Use HRP-conjugated secondary antibodies with enhanced chemiluminescence for sensitive detection

• Exposure optimization: Begin with short exposures and increase as needed to capture optimal signal

For challenging samples or weak signals, sensitivity can be enhanced using signal amplification systems while maintaining specificity with longer and more stringent washing steps.

What controls should be included when using DNAJB5 antibodies for immunohistochemistry or immunofluorescence?

Incorporating appropriate controls is essential for reliable DNAJB5 immunostaining experiments:

Essential Controls:

• Positive tissue control: Human heart tissue has been validated for strong DNAJB5 expression and should be included as a positive control

• Negative tissue control: Tissues known to have minimal DNAJB5 expression

• Technical negative controls:

  • Primary antibody omission (secondary antibody only)

  • Isotype control (matched rabbit IgG at equivalent concentration)

  • Blocking peptide competition (pre-incubation of antibody with immunizing peptide)

• Cellular localization control: Compare staining pattern with known subcellular distribution of DNAJB5

• Knockdown/knockout validation: When possible, include samples from DNAJB5-depleted cells or tissues to confirm specificity

For immunofluorescence studies in cell lines, HepG2 cells have been validated as a reliable positive control system . When analyzing neurodegenerative disease models, cortical neurons provide relevant biological context for DNAJB5 detection .

How should researchers interpret unexpected molecular weight variations when detecting DNAJB5 via Western blot?

While the predicted molecular weight of DNAJB5 is 39 kDa , researchers may encounter variations that require careful interpretation:

Potential causes and interpretations of molecular weight variations:

• Higher molecular weight bands (>39 kDa):

  • Post-translational modifications: Phosphorylation, ubiquitination, or SUMOylation

  • Incomplete denaturation: Ensure complete reduction of disulfide bonds

  • Protein-protein interactions: More stringent lysis conditions may be required

• Lower molecular weight bands (<39 kDa):

  • Proteolytic degradation: Enhance protease inhibitor cocktail

  • Alternative splicing variants: Verify against known isoforms

  • Cross-reactivity with related DnaJ family proteins: Validate with alternative antibodies

• Multiple bands:

  • Cell/tissue-specific expression of isoforms: Compare with reference databases

  • Partial proteolysis: Optimize sample preparation protocols

  • Non-specific binding: Increase antibody dilution or washing stringency

To differentiate between technical artifacts and biologically relevant variations, researchers should employ orthogonal methods of validation, including mass spectrometry or immunoprecipitation followed by protein identification.

What are the common technical challenges when working with DNAJB5 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when using DNAJB5 antibodies:

• Background signal in immunohistochemistry:

  • Increase antibody dilution to 1:100-1:200

  • Extend blocking time with 5-10% normal serum

  • Include 0.1-0.3% Triton X-100 in antibody diluent to reduce non-specific binding

  • Optimize antigen retrieval conditions (citrate buffer pH 6.0 typically works well)

• Weak or absent signal in Western blot:

  • Ensure adequate protein loading (30-50 μg)

  • Verify protein transfer efficiency with reversible staining

  • Try different epitope-targeting antibodies (e.g., N-terminal vs. C-terminal)

  • Enrich samples through immunoprecipitation before Western blotting

• Variability between experiments:

  • Standardize lysate preparation procedures

  • Use internal loading controls consistently

  • Document antibody lot numbers and prepare larger working aliquots

  • Implement quantitative normalization methods

• Cross-reactivity with other DNAJ family proteins:

  • Validate with recombinant DNAJB5 protein as positive control

  • Include samples from DNAJB5 knockout/knockdown systems

  • Use antibodies targeting unique regions of DNAJB5

These optimization strategies should be systematically tested and documented to establish reliable protocols for specific experimental systems.

How can researchers effectively utilize DNAJB5 antibodies in studying protein aggregation mechanisms in neurodegenerative disease models?

DNAJB5 has emerged as an important regulator of protein aggregation in neurodegenerative disorders, particularly those involving TDP-43 pathology . Researchers can leverage DNAJB5 antibodies for several advanced applications:

• Co-localization studies: Combine DNAJB5 antibodies with markers of protein aggregation (TDP-43, polyglutamine proteins) using multi-color immunofluorescence to assess physical interactions.

• Client protein identification: Employ DNAJB5 antibodies for co-immunoprecipitation followed by mass spectrometry to identify novel client proteins in disease-specific contexts.

• Dynamic protein response monitoring: Use DNAJB5 antibodies to track the temporal changes in chaperone recruitment during stress response and aggregation formation.

• Therapeutic modulation assessment: Evaluate changes in DNAJB5 expression and localization following treatment with compounds designed to enhance proteostasis.

• Comparative analysis across disease models: Apply DNAJB5 immunostaining across multiple neurodegenerative disease models to identify common and distinct patterns of chaperone activity.

When designing these experiments, researchers should consider that DNAJB5 increases have been observed specifically in the early stages of disease models, suggesting a transient protective response that may be suppressed in later disease stages .

What are the methodological considerations for studying DNAJB5 interactions with the HSP70 chaperone machinery?

DNAJB5 functions as a co-chaperone for the HSP70 (HSPA) system in supporting protein degradation via the proteasome . When investigating these functional interactions, researchers should consider:

• Co-immunoprecipitation optimization:

  • Use mild lysis conditions (e.g., 0.5% NP-40) to preserve protein complexes

  • Include ATP and/or ADP in buffers to stabilize different conformational states

  • Consider cross-linking approaches for transient interactions

• Functional assays:

  • Luciferase refolding assays using destabilized luciferase mutants (e.g., Fluc DM - R188Q/R261Q)

  • In vitro reconstitution with purified components to assess direct interactions

  • ATPase assays to measure DNAJB5 stimulation of HSP70 activity

• Domain mapping experiments:

  • Generate and express truncation mutants to identify interaction domains

  • Focus on the C-terminal TTK-LKS motif region, which has been shown to be critical for inhibiting certain types of protein aggregation

• Client protein specificity:

  • Compare DNAJB5's effect on different aggregation-prone proteins

  • Distinguish between effects on amyloid formation versus non-amyloid aggregation

Understanding these interactions is particularly relevant since DNAJB6 and DNAJB8 possess distinct regions for binding different types of aggregation-prone substrates, and similar mechanisms likely exist for DNAJB5 .

What experimental approaches can be used to validate DNAJB5 antibody specificity in knockout or knockdown systems?

• Genetic knockout models:

  • Use CRISPR/Cas9 to generate DNAJB5 knockout cell lines

  • Verify knockout efficiency at the DNA level (sequencing) and RNA level (RT-PCR)

  • Demonstrate absence of DNAJB5 signal in knockout cells via Western blot and immunostaining

• RNA interference approaches:

  • Implement siRNA or shRNA targeting DNAJB5

  • Establish dose-dependent reduction in protein levels

  • Include non-targeting controls with matched transfection conditions

• Overexpression validation:

  • Express tagged DNAJB5 constructs and demonstrate co-labeling with the antibody

  • Show increased signal intensity proportional to expression levels

  • Perform competition experiments with untagged DNAJB5

• Cross-species validation:

  • Compare reactivity across species with known sequence homology

  • Correlate signal intensity with evolutionary conservation of epitopes

• Orthogonal detection methods:

  • Validate with multiple antibodies targeting different epitopes

  • Confirm protein identity using mass spectrometry

These validation approaches are particularly important when studying DNAJB5 in the context of neurodegenerative diseases, where antibody cross-reactivity with other aggregated proteins could confound interpretations .

How does DNAJB5 function in TDP-43 proteinopathies and what experimental tools can assess this relationship?

DNAJB5 has been identified as a protein folding factor that can decrease TDP-43 aggregation in cellular and neuronal models . Researchers investigating this relationship should consider:

• Temporal expression patterns:

  • DNAJB5 increases specifically in early disease stages in mouse models of TDP-43 proteinopathy

  • This suggests a potential early protective response that becomes suppressed as disease progresses

• Functional relationship assessment:

  • Overexpression studies have demonstrated that DNAJB5 can reduce TDP-43 aggregation in HEK293 cells and primary cortical neurons

  • Knockout of Dnajb5 exacerbates motor impairments associated with cytoplasmic TDP-43 expression in mouse models

• Experimental tools for investigation:

  • rNLS8 mouse model: Expresses cytoplasmic TDP-43 in a doxycycline-dependent manner

  • TDP-map webtool: Allows comparison of transcriptomic and proteomic datasets from mouse and human TDP-43 proteinopathies

  • Immunohistochemical co-localization: Assesses physical association between DNAJB5 and TDP-43 aggregates

  • Biochemical fractionation: Separates soluble from insoluble protein fractions to quantify aggregation states

These findings suggest that enhancing DNAJB5 function could represent a potential therapeutic strategy for ALS and FTLD, highlighting the importance of mechanistic studies in this area .

What are the methodological considerations for analyzing DNAJB5 expression changes in longitudinal disease models?

Detecting meaningful changes in DNAJB5 expression throughout disease progression requires careful experimental design:

• Sampling strategy:

  • Implement multiple timepoints spanning pre-symptomatic, disease onset, progression, and terminal stages

  • Include recovery phase timepoints when using inducible disease models

• Region-specific analysis:

  • Isolate specific brain regions separately (cortex, hippocampus, spinal cord) as DNAJB5 shows region-specific patterns

  • Consider laser capture microdissection for cell-type specific analysis

• Multi-level assessment:

  • RNA analysis: qRT-PCR and RNA-seq for transcriptional changes

  • Protein analysis: Western blot and immunohistochemistry for translation and localization

  • Functional analysis: Co-immunoprecipitation to track changing protein interactions

• Quantification methods:

  • Use weighted correlation network analysis to identify longitudinally correlated protein changes

  • Implement unbiased stereological counting for immunohistochemical analysis

  • Apply normalization to multiple housekeeping controls to account for disease-induced changes

• Correlation with functional outcomes:

  • Track behavioral phenotypes in parallel with molecular changes

  • Correlate DNAJB5 levels with aggregation markers and neurodegeneration metrics

The longitudinal profiling of the cortex proteome throughout TDP-43-driven disease progression has revealed that cytoplasmic TDP-43 accumulation drives dynamic changes, with protein folding factors like DNAJB5 increasing specifically prior to disease onset .

How can researchers effectively compare DNAJB5 function between animal models and human pathological specimens?

Translating findings between animal models and human disease requires careful consideration of several factors:

• Comparative expression analysis:

  • Use validated DNAJB5 antibodies that recognize epitopes conserved between species

  • Implement parallel processing of animal and human samples to minimize technical variation

  • Consider targeted mass spectrometry approaches for absolute quantification

• Cross-species validation approaches:

  • Utilize human postmortem tissues from patients with TDP-43 proteinopathies

  • Compare findings with animal models at equivalent disease stages

  • Assess DNAJB5 levels in induced pluripotent stem cell (iPSC)-derived neurons from patients

• Data integration strategies:

  • Leverage resources like the TDP-map webtool to compare transcriptomic and proteomic datasets

  • Apply bioinformatic approaches to identify conserved regulatory networks

  • Calculate correlation coefficients between mouse model proteomes and human autopsy-derived tissues

• Technical considerations for human samples:

  • Account for postmortem interval effects on protein stability

  • Implement appropriate antigen retrieval methods for formalin-fixed tissues

  • Document patient demographics and clinical features for cohort stratification

Research has shown that late disease proteomic signatures of rNLS8 mouse cortex strongly correlate with changes in human autopsy-derived TDP-43 proteinopathy tissues, indicating commonality of disease processes . This suggests that findings regarding DNAJB5 function in mouse models may have direct relevance to human disease mechanisms.